Group items tagged

The American Diabetes Association is requesting applications for research focused on the impact of diabetes on COVID-19 and the impact of COVID-19 on diabetes and its complications. Recent clinical experience has shown that people with diabetes are at higher risk of death from COVID19 and that COVID-19 drives an increased risk of hyperglycemia and other complications in those with and without diabetes. This is in addition to the risk due to advanced age and chronic disease. Both the biological mechanisms underlying this risk and how to minimize it remain poorly understood. There is an urgent need for research to understand the impact of diabetes on COVID-19 and vice versa. This is true at a basic and clinical level.

Grants of up to $1.62 million over five to seven years will be awarded to support investigators with an innovative basic, clinical, translational, epidemiological, or health services research initiative relevant to any diabetes type, diabetes-related disease state, or diabetes complication. The program seeks to bring new perspectives to diabetes research by offering three types of funding: support for the transition from trainee to independent investigator, support for early-career diabetes investigators, and support for established investigators new to diabetes research.

his Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers, formerly named Diabetes Endocrinology Research Centers (DERCs) and Diabetes Research and Training Centers (DRTCs).Diabetes Research Centers are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases.

This Funding Opportunity Announcement (FOA) invites applications for a Data Coordinating Center (DCC) that will support the Diabetic Foot Consortium (DFC) for clinical research on diabetic foot ulcers. The first studies will validate biomarkers that predict healing or response to therapy and assess infection or recurrence risk. Future research may involve clinical trials and studies on the pathophysiology of diabetic foot ulcers. Given the clinical complexity of diabetic wound healing, the applicant must have experience serving as the DCC on clinical studies of diabetic foot ulcers. The DCC will provide overall project coordination, administration, quality control, data management, and biostatistical support.

This Funding Opportunity Announcement (FOA) invites applications for a Center for Identification and Study of Individuals with Atypical Diabetes Mellitus (U54). The purpose of this Center is to: foster the study of individuals with rare/atypical forms of diabetes mellitus; identify and analyze phenotypic and genotypic defects that may provide insights into more common, heterogeneous forms of Type 2 diabetes mellitus (T2DM) in the general population; and develop a community resource to advance research in this area through the collection and dissemination of data and samples for access by the broad research community. To achieve this goal, the Center should support the following primary research endeavors: (1) develop a process for identifying and studying individuals/families with rare and uncharacterized forms of diabetes and (2) create and manage a database and biospecimen repository of rare/atypical forms of diabetes for use by the broader research community in future analyses.

The award program is designed to advance the understanding of mechanisms underlying the development of renal complications in people with diabetes and improve the treatment and management of people with chronic kidney disease and diabetes. Proposals for basic, clinical, or translational science projects, including fundamental biological research, mechanistic and outcome-based clinical studies, behavioral research, database, and epidemiologic research, will be considered. Studies focused on improving the evidence base for optimal treatment and management of chronic kidney disease in a diabetes setting and increasing understanding of the development of renal complications in people with diabetes are encouraged.

This Funding Opportunity Announcement (FOA) invites applications for a Data Coordinating Center (DCC) that will support the Diabetic Foot Consortium (DFC) for clinical research on diabetic foot ulcers. The first studies will validate biomarkers that predict healing or response to therapy and assess infection or recurrence risk.  Future research may involve clinical trials and studies on the pathophysiology of diabetic foot ulcers.  The applicant must have experience serving as the DCC for studies on complex, clinical conditions because of the multi-faceted nature of diabetic foot ulcers and their treatments.  The DCC will provide overall project coordination, administration, quality control, data management, and biostatistical support.

For calendar year 2014, the Iacocca Family Foundation will accept grant applications to support innovative and promising research projects that will lead to a cure for type 1 diabetes.  The Foundation will accept novel projects which directly accelerate a cure for type 1 diabetes or inform the understanding of the disease by a related or complementary mechanism of action.  Investigators in traditional type 1 diabetes research, as well as investigators currently working on other autoimmune diseases are encouraged to apply, provided that the proposed project focuses directly on type 1 diabetes and supports the mission of the Foundation. The deadline for submission of proposals is Friday, January 31, 2014.  All applications must be e-mailed in PDF format to the Foundation by 5:00pm EST on January 31, 2014, as well as postmarked and mailed.

The purpose of this Funding Opportunity Announcement (FOA) is to continue the SEARCH for Diabetes in Youth Study. The overarching goal of SEARCH is to provide population-based data on the incidence and prevalence of diabetes and its complications in U.S. youth. SEARCH has recruited a cohort of youth with diabetes who have been followed longitudinally. The purpose of this FOA is to continue follow-up of the SEARCH cohort to understand the clinical course of youth-onset diabetes, including the incidence of acute and chronic complications, including mortality, and processes of care and quality of life.

The purpose of this Funding Opportunity Announcement (FOA) is to continue the SEARCH for Diabetes in Youth Study. The overarching goal of SEARCH is to provide population-based data on the incidence and prevalence of diabetes and its complications in U.S. youth. SEARCH has recruited a cohort of youth with diabetes who have been followed longitudinally. The purpose of this FOA is to continue follow-up of the SEARCH cohort to understand the clinical course of youth-onset diabetes, including the incidence of acute and chronic complications, including mortality, and processes of care and quality of life.  - See more at: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-508.html#sthash.WZygd0KM.dpuf

he purpose of this Center is to: foster the study of individuals with rare/atypical forms of diabetes mellitus; identify and analyze phenotypic and genotypic defects that may provide insights into more common, heterogeneous forms of Type 2 diabetes mellitus (T2DM) in the general population; and develop a community resource to advance research in this area through the collection and dissemination of data and samples for access by the broad research community. To achieve this goal, the Center should support the following primary research endeavors: (1) develop a process for identifying and studying individuals/families with rare and uncharacterized forms of diabetes and (2) create and manage a database and biospecimen repository of rare/atypical forms of diabetes for use by the broader research community in future analyses.

Pathway supports innovative basic, clinical, translational, epidemiological, behavioral, or health services research relevant to any diabetes type, diabetes-related disease state, or diabetes complication. The Association seeks exceptional candidates from a broad range of disciplines, including medicine, biology, chemistry, computing, physics, mathematics and engineering.

Research Awards provide grant support to both new and established investigators. Basic Science Awards are designed to support basic science research in any area relevant to the etiology or pathophysiology of diabetes and its complications, while Clinical Science and Epidemiology Awards support patient-oriented clinical research and epidemiology research in diabetes. The Translational Science Award supports research that accelerates the transition of scientific discoveries into clinical applications. Innovation Awards are intended to support creative proposals that may lack preliminary data but hold significant promise for advancements in the prevention, cure or treatment of diabetes.

Today, nearly one in eight American adults has diabetes, and diagnosed diabetes costs the United States $245 billion each year. By 2050, if our current course as a nation continues, one in three American adults will have diabetes. The cost to this country - in lives, lost productivity and hard dollars - will be an enormous personal and societal burden that could overwhelm our healthcare system and bankrupt our nation. America has never faced anything like this before, and we are working to ensure that this frightening future never comes to fruition. Researchers are making important progress in the fight against this disease, but frankly, it's not fast enough, it's not dramatic enough, it's not good enough. There's a reason for that: It's not funded enough.

The American Diabetes Association's Core Research Program funds research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of diabetes.  To that end, the association invites applications for its Junior Faculty Development (JFD) and Minority Junior Faculty Development (JDFM) Awards Through the JDF program, grants of $138,000 per year plus optional student loan repayment ($10,000 per year) will be awarded over two to four years to help early investigators establish their independence in diabetes research.

NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms will serve as the foundation for NIDDK's advanced strategy to identify new and novel therapeutics for diabetes. The utility and validity of model systems developed under this initiative will be measured, in part, through the ability of known diabetes therapeutic agents and biomarkers to influence biology of the system, using best practices and rigorous study design. The need for high-quality, well-characterized isogenic/patient derived iPSC (induced pluripotent stem cell) lines and standardized differentiation procedures is a critical step in turning disease-specific lines into tools for discovery. In the future, iPSC-based human tissue chips could play a central role in drug development, testing, screening, drug repurposing and toxicity testing.

The American Diabetes Association's Core Research Program funds research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of diabetes.  To that end, the ADA is inviting applications for its Training Awards, including a Postdoctoral Fellowship (PDF) and Minority Postdoctoral Fellowship (PMF). Through the PDF program, a salary stipend of up to $55,581 per year for up to three years, plus $5,000 annually for training and a $5,000 fringe benefit allowance, will be awarded to postdoctoral researchers in support of high-quality training in an environment conducive to beginning a career in diabetes research.

This FOA will support research on the development of biomarkers for the complications of type 1 diabetes that will use minimally or non-invasive measures of blood vessels and nerves in the eye.  A critical obstacle for preventing and treating diabetes complications is the paucity of both biomarkers that can detect changes in blood vessels and nerves before clinical signs develop and surrogate end-points that can measure early responses to an intervention.  Given the accessibility of the blood vessels and nerves in the eye for visualization, this FOA invites applications for research using the eye to visualize the development of diabetes complications in the eye and other tissues, such as the kidney, brain, heart and peripheral nerves.      

This FOA will support research on the development of biomarkers for the complications of type 1 diabetes that will use minimally or non-invasive measures of blood vessels and nerves in the eye. A critical obstacle for preventing and treating diabetes complications is the paucity of both biomarkers that can detect changes in blood vessels and nerves before clinical signs develop and surrogate end-points that can measure early responses to an intervention. Given the accessibility of the blood vessels and nerves in the eye for visualization, this FOA invites applications for research using the eye to visualize the development of diabetes complications in the eye and other tissues, such as the kidney, brain, heart and peripheral nerves.

This FOA seeks applications for clinical trials testing interventions targeting diabetes distress in individuals with T1D and/or their caregivers, with the goal of understanding whether lowering diabetes distress will improve glycemic control and quality of life.